1. Home
  2. BOBS vs MLYS Comparison

BOBS vs MLYS Comparison

Compare BOBS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bob's Discount Furniture Inc. Common Stock

BOBS

Bob's Discount Furniture Inc. Common Stock

N/A

Current Price

$19.58

Market Cap

2.4B

ML Signal

N/A

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$15.41

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOBS
MLYS
Founded
1991
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
1.9B
IPO Year
2026
2023

Fundamental Metrics

Financial Performance
Metric
BOBS
MLYS
Price
$19.58
$15.41
Analyst Decision
Buy
Strong Buy
Analyst Count
13
11
Target Price
$22.77
★ $45.22
AVG Volume (30 Days)
711.3K
★ 1.8M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 37.43
EPS
★ 0.76
N/A
Revenue
N/A
N/A
Revenue This Year
$10.29
N/A
Revenue Next Year
$7.31
N/A
P/E Ratio
$39.85
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.74
$15.33
52 Week High
$23.11
$47.65

Technical Indicators

Market Signals
Indicator
BOBS
MLYS
Relative Strength Index (RSI) 78.77 28.91
Support Level $11.80 N/A
Resistance Level $23.11 $31.19
Average True Range (ATR) 1.00 1.42
MACD 0.45 -0.40
Stochastic Oscillator 96.90 6.21

Price Performance

Historical Comparison
BOBS
MLYS

About BOBS Bob's Discount Furniture Inc. Common Stock

Bobs Discount Furniture Inc operates as a furniture retailer offering a wide variety of merchandise assortments across several categories, including upholstery, case goods, bedding, and other. The company generates the majority of its revenue from the sale of its products through its retail stores.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: